Literature DB >> 2593715

Chronic myelomonocytic leukemia: natural history and prognostic determinants.

A Tefferi1, H C Hoagland, T M Therneau, R V Pierre.   

Abstract

A retrospective clinical review of 41 patients with chronic myelomonocytic leukemia revealed a median age of 66 years and a male:female ratio of 2.4:1. The disease was preceded by a myelodysplastic syndrome of a different subtype in 24% of the patients and transformed into acute leukemia in 24%. Splenomegaly was present in 54% of the patients and reached massive proportions in 24%. Chromosomal abnormalities occurred in 34% of those studied, most commonly in the younger age group; the most frequent were trisomy 8, monosomy 7, and deletions involving the long arms of chromosomes 20 and X. Polyclonal hypergammaglobulinemia was detected in 47% of the patients in whom serum protein electrophoresis was done. The median survival was 3 years. With use of univariate analysis, the statistically significant prognostic determinants were hemoglobin level, the "modified Bournemouth score," and bone marrow blast cell percentage. When these factors were subjected to a multivariate analysis, only bone marrow blast cell percentage was an independent prognostic determinant. Orally administered hydroxyurea controlled leukocytosis and splenomegaly in some patients without affecting the overall prognosis.

Entities:  

Mesh:

Year:  1989        PMID: 2593715     DOI: 10.1016/s0025-6196(12)61287-7

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  11 in total

1.  Myelodysplastic syndrome: An update on diagnosis and therapy.

Authors:  Ahrin Koppel; Gary Schiller
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

2.  Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.

Authors:  Véronique Gelsi-Boyer; Nathalie Cervera; François Bertucci; Mandy Brecqueville; Pascal Finetti; Anne Murati; Christine Arnoulet; Marie-Joelle Mozziconacci; Ken I Mills; Nicholas C P Cross; Norbert Vey; Daniel Birnbaum
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

Review 3.  Myelodysplastic syndrome: an update on diagnosis and therapy.

Authors:  Ahrin Koppel; Gary Schiller
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

4.  Lymph node disease with lymphocytic abnormal chromatin clumping in a myelodysplastic/myeloproliferative syndrome.

Authors:  J Gardais
Journal:  J Clin Pathol       Date:  1993-02       Impact factor: 3.411

Review 5.  Models of Prognostication in Chronic Myelomonocytic Leukemia.

Authors:  Francesco Onida
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

6.  Chronic inflammatory demyelinating polyneuropathy accompanied by chronic myelomonocytic leukemia: possible pathogenesis of autoimmunity in myelodysplastic syndrome.

Authors:  Atsushi Isoda; Atsushi Sakurai; Yoshiyuki Ogawa; Yuri Miyazawa; Akio Saito; Morio Matsumoto; Morio Sawamura
Journal:  Int J Hematol       Date:  2009-07-09       Impact factor: 2.490

Review 7.  Therapy for Chronic Myelomonocytic Leukemia in a New Era.

Authors:  Tamara K Moyo; Michael R Savona
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 8.  How to interpret and pursue an abnormal complete blood cell count in adults.

Authors:  Ayalew Tefferi; Curtis A Hanson; David J Inwards
Journal:  Mayo Clin Proc       Date:  2005-07       Impact factor: 7.616

9.  Leukemic infiltration in the settings of acute respiratory failure.

Authors:  M Fayed; T Evans; H Abdulhaq
Journal:  Oxf Med Case Reports       Date:  2019-12-09

10.  Anti-N-methyl-D-aspartate receptor encephalitis associated with chronic myelogenous leukemia, causality or coincidence? A case report.

Authors:  Ying Yu; Jun-Li Liu; Dai-Shi Tian
Journal:  BMC Neurol       Date:  2022-04-23       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.